So with revenue jumping up to around $10m annually I would imagine FDA approval could see us trading at high forward PE valuations. Maybe 20 to 30 x earnings?
That would be optimum before NASDAQ listing, a market cap of around $200m would make raising a further $30-50m a breeze.
Ann: CardieX Announces Significant New Clinical Trial Agreement, page-15
Add CDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.1¢ |
Change
0.001(1.67%) |
Mkt cap ! $17.94M | |||
| Open | High | Low | Value | Volume |
| 5.8¢ | 6.1¢ | 5.5¢ | $9.816K | 165.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8395 | 6.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.2¢ | 8000 | 1 |
View Market Depth
| Last trade - 15.43pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
6.1¢ |
Change
0.001 ( 3.39 %) |
||||
| Open | High | Low | Volume | ||
| 5.8¢ | 6.4¢ | 5.6¢ | 25037 | ||
| Last updated 15.43pm 05/06/2024 ? | |||||
| CDX (ASX) Chart |